Indianapolis, Indiana 46202


Hypothesis: Elevated miR210 in the epidermis (outer layer of skin) of ischemic human wound edge tissue (tissue that has a lack of blood flow to it) is associated with poor healing outcome in a setting of standard clinical care. Aim of the study: To determine whether elevated miR-210 in the epidermis of ischemic human wound edge tissue is associated with poor healing outcome in a setting of standard clinical care. This study will last 14 weeks. Adult patients, who are non-diabetic or tightly controlled diabetic, and, who have chronic venous leg ulcers, that are not infected and have been open/not healed for at least 12 weeks, will be enrolled in this study. Patients will be recruited from the Indiana University Health Comprehensive Wound Center (CWC). On days 0, 14 and 28, patients will have the following performed: measurements and photographs taken of their wound; TCOM (transcutaneous oxygen measurement) or ABI to measure the amount of oxygen in the wound tissue; and two 3-mm punch biopsies from the same wound/ulcer. Biopsies will not be taken if the wound has closed by day 14 or day 28. Additionally, patients' medical records will be reviewed throughout the study for 98 days (14 weeks) after enrollment to determine the final status of the wound as healed or not-healed. ABI will be completed per study personnel at initial visit for all consented subjects to ensure subject eligibility (as listed TCOM<30 mmHg in exclusion criteria). If ABI's are unable to be obtained, TCOM will be performed. There will be a total of 5 visits for this study (6 total visits for patients with open wounds on day 28 of the study). Visits will occur on days 0, 7, 14, 21,28.

Study summary:

The study is designed as 28-day prospective longitudinal observational study including a 98 day (14 week) follow-up photography of the wound to test whether wounds open on day 28 have closed on week 14, or if they have remained chronically open. On days 0, 14 and 28 after enrollment, wound images will be obtained. Wound photographs are a part of standard care when patients come to the Comprehensive Wound Center (CWC). Images do not include the part of body that could lead to identification of the participants. In addition, following standard of care, two biopsies will be taken - one biopsy will be used for laser capture microdissection (LCM) and immunohistochemistry studies, while the other will be used for determination of infection status using quantitative bacterial cultures and Scanning Electron Microscopy (SEM) imaging for biofilm phenotyping. The following will be completed on days 0, 14 and 28: 1. Wound measurements - Photographs for digital planimetry to measure wound area. 2. Two Wound-edge biopsies (3mm) - following wound bed preparation with 1% lidocaine local anesthetic, as required, two punch biopsies (3 mm each) will be obtained from the wound-edge (the leading 3mm edge of the skin at the perimeter) of the same wound/ulcer. 3. Data Collection - the following information will be collected during the enrollment visit and updated at each visit (weekly - on days 0, 7, 14, 21, 28 and 98 (week 14) ), as necessary, and entered onto the data collection form: Age; Sex; Race/Ethnicity; Current medications; Transcutaneous oxygen measurement(TCOM) <30 mmHg or ABI < 0.8; Wound location & Etiology; Other associated illnesses; Wound care modality/treatment; and Nutritional status will be recorded as documented by albumin levels and chart records. Healing outcome: Wound photography will be performed every 7 days (every week) as a part of the current standard of care. Based on wound measurements from days 0 and 28 , patients will be classified as either healing or non-healing, per criteria described in the study proposal/protocol. There will be a total of 5 visits for this study (6 total visits for patients with open wounds on day 28 of the study). Visits will occur on days 0, 7, 14, 21 and 28.


Inclusion Criteria: - Ages 30 + years - Presence of 1 or more non-neuropathic venous stasis leg ulcer(s) (VLU) confirmed by vascular duplex - Chronic - Wound open >4 weeks Exclusion Criteria: - Individuals who are deemed unable to understand the procedures, risks and benefits of the study (i.e., informed consent) will be excluded - Pregnant women - Diabetes with hemoglobin A1C > 9% - Subjects with marked immunodeficiency (i.e., patients with HIV/AIDS, organ transplant, and/or cancer) - Arterial disease (TCOM<30 mmHg or ABI < 0.6)



Primary Contact:

Principal Investigator
Chandan K Sen, PhD
Indiana University Department of Surgery

Jennifer Mohnacky, RDN
Phone: 317-278-2715

Backup Contact:

Sashwati Roy, PhD
Phone: 317-278-2706

Location Contact:

Indianapolis, Indiana 46202
United States

Jennifer Mohnacky, RDN
Phone: 317-278-2715

Site Status: Recruiting

Data Source:

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.